FENTANYL Drug Patent Profile

Which patents cover Fentanyl, and when can generic versions of Fentanyl launch?

Fentanyl is a drug marketed by Cephalon, Abbott, Fresenius Kabi Usa, Hikma, Hospira, Watson Labs, Exela Pharma, Dr Reddys Labs Sa, Actavis Labs Fl Inc, Par Pharm, Specgx Llc, Astrazeneca, Dr Reddys, Actavis Labs Ut Inc, Difgen Pharms, Kindeva, Lavipharm Labs, Mayne Pharma, Mylan Technologies, Noven, and Zydus Pharms. and is included in twenty-nine NDAs.

The generic ingredient in FENTANYL is fentanyl. There are thirty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

Summary for FENTANYL

US Patents:	0
Applicants:	21
NDAs:	29
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FENTANYL

Paragraph IV (Patent) Challenges for FENTANYL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBSYS	Sublingual Spray	fentanyl	0.1 mg/spray, 0.2 mg/spray, 0.6 mg/spray, 0.8 mg/spray, 1.2 mg/spray, 1.6 mg/spray	202788	1	2017-12-07
SUBSYS	Sublingual Spray	fentanyl	0.4 mg/spray	202788	1	2017-05-22

US Patents and Regulatory Information for FENTANYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	209655-002	Jan 24, 2023		DISCN	No	No
Zydus Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	209655-007	Jan 24, 2023		DISCN	No	No
Specgx Llc	FENTANYL CITRATE	fentanyl citrate	TROCHE/LOZENGE;TRANSMUCOSAL	078907-005	Oct 30, 2009		DISCN	No	No
Par Pharm	FENTANYL CITRATE	fentanyl citrate	TROCHE/LOZENGE;TRANSMUCOSAL	077312-002	Oct 30, 2009		DISCN	No	No
Difgen Pharms	FENTANYL-62	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449-007	Dec 6, 2017	AB	RX	No	No

International Patents for FENTANYL

See the table below for patents covering FENTANYL around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	175779
Austria	300937
Germany	69027216
European Patent Office	0200490	COMPOSITIONS FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
Australia	681323

Supplementary Protection Certificates for FENTANYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1635783	C300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
1635783	300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126

Fentanyl: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Fentanyl, a synthetic opioid with potent analgesic properties, faces complex market and regulatory environments influencing its investment potential. While legal pharmaceutical use under strict controls remains lucrative, the black-market trade and associated regulatory risks substantially impact valuation, commercialization, and future growth. This analysis provides an in-depth review of the current market landscape, competitive dynamics, regulatory frameworks, financial trajectories, and strategic considerations for investors contemplating fentanyl-related assets or ventures.

---

What Are the Market Dynamics Surrounding Fentanyl?

Market Size and Growth Trends

Parameter	Figures / Trends	Source
Global opioid market valuation	Estimated at $20 billion (2021), with expected CAGR of ~4% through 2026	Grand View Research[1]
Pharmaceutical fentanyl sales	Approx. $2.5 billion (2022), representing ~12.5% of global opioid sales	IQVIA[2]
Illicit fentanyl market (estimates)	Annual street sales exceeding $72 billion globally (2020)	DEA[3]
Growth driver	Rising pain management needs, shift towards synthetic opioids	IMS Health, 2022

Key Market Segments

Segment	Market Share	Characteristics
Pharmaceutical (Medical Use)	~75%	Chronic pain management, cancer pain, anesthesia
Illicit Market	~25%	Counterfeit pills, smuggling, clandestine labs

Regulatory and Legal Environment

• United States: The Drug Enforcement Administration (DEA) classifies fentanyl as a Schedule II controlled substance; strict licensing and distribution controls apply.
• European Union: Regulates fentanyl under the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); licensed medical use permitted with rigorous oversight.
• Emerging markets: Varying degrees of control; some countries face lax enforcement increasing illicit risks.

Market Drivers and Restraints

Drivers	Restraints
Growing chronic pain prevalence	High regulatory hurdles
Advancements in pain management therapies	Risks of overdose, abuse, and litigation
Development of abuse-deterrent formulations	Regulatory delays and approval setbacks
Opioid prescription reforms reducing excess prescribing	Public health campaigns targeting opioid misuse

---

What Is the Investment Scenario for Fentanyl?

Pharmaceutical Development and Patents

Aspect	Status / Outlook	Implications
Patent expirations	Many fentanyl formulations patented into early 2020s, with some expiring by 2030	Opportunities for generic entrants
Novel formulations (transdermal, buccal, intranasal)	Rising investments to develop abuse-deterrent and novel delivery systems	Potential for premium pricing and exclusivity
Biosimilars and generics	Increased market entry post-patent expiry	Price erosion, margin compression

Manufacturing and Supply Chain Considerations

• Legal manufacturing: Usually involves licensed compounding and pharmaceutical operations under strict regulatory compliance.
• Illicit manufacturing: Dominates the black market with clandestine labs, often unsafe, and subject to interdiction risks.
• Supply chain risks: Theft, diversion, regulatory interception, and geopolitical factors impacting raw material access (e.g., precursor chemicals).

Investment Opportunities and Risks

Opportunities	Risks
Development of abuse-deterrent formulations (ADFs)	Regulatory delays, safety concerns, and reimbursement hurdles
Expansion into emerging markets	Divergent regulatory environments and enforcement
Licensing and partnership with pharma companies	Intellectual property disputes
Combating illicit trade through new technologies	Legal liabilities, reputation risks

---

What Are the Financial Trajectories for Fentanyl?

Revenue and Profitability Trends

Metric	2021 / 2022	Forecast / 2025	Notes
Global pharmaceutical fentanyl sales	~$2.5 billion	~$3 billion	CAGR of ~4% driven by demand for pain management
Cost of manufacturing	Approx. 15-20% of revenue	Marginally reduced with generics	Economies of scale may reduce costs
Market penetration of novel formulations	10-15% (by 2025)	Potential to increase significantly	Innovation drives premium pricing
Illicit fentanyl sales	Estimated at ~$72 billion annually	Not directly quantifiable	Largely untraceable but influences healthcare costs

Competitive Landscape & Leading Players

Company	Market Share	Focus Area	Strategic Moves
Johnson & Johnson	Major producer	Transdermal fentanyl patches	R&D on abuse-deterrent drug delivery
AbbVie / AbbVie (formerly)	Significant player	Various formulations, generic development	Patent defenses, licensing deals
Mylan / Teva	Generic dominance	Cost-effective formulations	Price competition, patent challenges
Small biotech firms	Niche players	Innovation in formulations, delivery systems	Partnerships with major pharma, licensing

Regulatory and Market Entry Impact on Financials

Factor	Effect on Financial Trajectory	Actions for Investors
Patent expiry	Price erosion, increased generics	Focus on innovator companies with proprietary formulations
Regulatory approvals of novel formulations	Premium pricing, higher margins	Invest in firms developing innovative delivery systems
Enforcement actions against illicit trade	Reduced black-market volume	Lower societal costs, potential for legal reforms

---

Comparison with Other Synthetic Opioids

Compound	Potency (times morphine)	Legal Status	Market Focus	Investment Focus
Fentanyl	50-100x	Schedule II (US)	Medical, illicit market	Development of new formulations, combat illicit trade
Sufentanil	~500x	Schedule II	Anesthesia, research	Specialized medical applications
Remifentanil	100-20,000x	Schedule II	Rapid-onset anesthesia	Niche anesthetic markets

---

Deep Dive: Policy Impact and Regulatory Frameworks

Global Regulatory Overview

Jurisdiction	Key Policies / Regulations	Impact on Investment
USA	Controlled Substance Act, DEA scheduling, REMS programs	Stringent controls tighten supply chain, elevate compliance costs
European Union	EU Opioid Regulation, EMA guidelines	Adds barriers but steady demand
China / India	Precursor chemical control laws	Supply chain vulnerabilities, import/export controls
Latin America	Variable enforcement, evolving legal standards	Market entry challenges but growth potential

Recent Policy Trends

• Prescription Monitoring Programs (PMPs): Reduce overprescribing, impacting pharmaceutical sales.
• Opioid Reform Legislation: Limits on prescription quantities, impacting revenue streams.
• Illicit Trade Crackdowns: Heighten risks for black-market operations, influencing supply.

---

FAQs

1. What are the main investment considerations when evaluating fentanyl-based pharmaceuticals?
   Focus on patent protections, formulation innovations, regulatory approval pipelines, and market penetration strategies, balanced against risks from regulation and illicit trade.

2. How does patent expiration affect fentanyl market dynamics?
   Patent expirations typically lead to increased generic competition, lowering prices and profit margins, but also open opportunities for innovative formulations with patent protection extensions.

3. What is the impact of regulatory changes on the fentanyl market?
   Stricter controls reduce supply and prescribing, potentially shrinking legal markets temporarily but could also stimulate innovation and illicit trade.

4. Is the illicit market for fentanyl a significant risk for investors?
   Yes; illicit trafficking magnifies regulatory and reputational risks for pharmaceutical companies and complicates market forecasting.

5. How do emerging markets influence the future fentanyl market?
   Growing healthcare demands combined with variable regulation can provide both opportunities and risks for investors targeting these regions.

---

Key Takeaways

• The pharmaceutical fentanyl market is mature with stable growth but faces considerable regulatory and societal headwinds.
• Patent cliffs and innovation in formulations offer potential premium pricing but are balanced against legal and ethical considerations.
• Illicit fentanyl trading significantly influences market perception, regulatory policies, and global health costs.
• Strategic investment should prioritize companies with proprietary technologies, robust compliance frameworks, and diversified market access.
• Monitoring policy developments in major jurisdictions is essential for risk mitigation and opportunity assessment.

---

References

[1] Grand View Research, "Opioid Market Size & Share," 2021.
[2] IQVIA, "Global Pharmaceutical Sales Data," 2022.
[3] Drug Enforcement Administration, "Fentanyl and Synthetic Opioids," 2020.